Results 71 to 80 of about 753,406 (101)

Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease. [PDF]

open access: yesMol Neurodegener
An H   +26 more
europepmc   +1 more source

3D Differentiation of Bone-Marrow Derived Mesenchymal Stromal Cells into the Keratocyte Lineage for Corneal Bioprinting. [PDF]

open access: yesAdv Healthc Mater
Taoum A   +8 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Managing treatment fluctuations in Parkinson disease

Neurology, 2019
The first truly effective medical therapy for Parkinson disease (PD), levodopa, was introduced in the 1960s. Patients had to take huge doses of levodopa, with treatment limited by peripheral decarboxylation of levodopa to dopamine by dopa decarboxylase ...
W. Metzer, F. B. Rodrigues
semanticscholar   +1 more source

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.

Journal of Infectious Diseases, 1995
R. V. Leeuwen   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy